Alps Advisors Inc Amylyx Pharmaceuticals, Inc. Transaction History
Alps Advisors Inc
- $14.1 Billion
- Q1 2024
A detailed history of Alps Advisors Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 139,250 shares of AMLX stock, worth $246,472. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139,250
Previous 49,728
180.02%
Holding current value
$246,472
Previous $731,000
45.96%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding AMLX
# of Institutions
183Shares Held
50.3MCall Options Held
5.84MPut Options Held
2.06M-
Vanguard Group Inc Valley Forge, PA5.35MShares$9.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$7.92 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.94MShares$5.21 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.47MShares$4.37 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$3.67 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $104M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...